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Background. A negative association between the polymorphism F214L and type 1 thymidine analogue (TA)
mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of
F214L has not been evaluated.
Methods. We studied 590 patients from EuroSIDA who started TA therapy for the first time as part of potent
combination antiretroviral therapy (cART) and who were tested for genotypic resistance within the past 6 months.
End points were median reduction in the week 24 viral load and time to virological failure (2 consecutive VL
measurements 1400 copies/mL after at least 6 months of the TA-containing cART).
Results. In ART-naive patients, the prevalence of F214L was 17%. By 48 months after starting TA-based cART,
the proportion of patients who experienced virological failure was 16% in patients with 214L and 36% in those with
214F ( ). In a multivariable Cox regression model, the relative hazard of virological failure for patients withPp .03
214L compared with those with 214F was 0.22 (95% confidence interval, 0.07–0.72). In ART-experienced patients,
results were similar, and larger differences in virological response associated with the detection of 214L versus F were
observed in patients with M41L/T215Y and mixed TAM profiles detected before the initiation of cART.
Conclusions. This study provides evidence that the detection of polymorphism F214L is associated with a
favorable virological response to TA-based cART.
To date, a number of mechanisms are known to con-
tribute to decreased HIV susceptibility to nucleoside
reverse transcriptase inhibitors (NRTIs) [1–8]. One of
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these mechanisms consists of promoting the selective
excision of the incorporated nucleoside analogue from
the terminated DNA chain and is determined by a
group of mutations named “thymidine analogue (TA)
mutations” (TAMs; M41L, D67N, K70R, L210W,
T215Y/F, and K219E/Q). These mutations occur very
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frequently, predominantly under the pressure of antiretrovirals
such as zidovudine and stavudine, and cause cross-resistance
to other NRTIs [4–7].
Data from several studies suggest that TAMs are found in 2
distinct clusters defined by different mutation patterns (type 1
TAMs include M41L, L210W, and T215Y, and type 2 TAMs
include D67N, K70R, T215F, and K219Q/E) [9–12], and recent
statistical analyses have confirmed that the clustering is a real
phenomenon [13]. Nonetheless, this distinction should not be
considered absolute because several mutations (especially M41L
and D67N) from one group can coexist with those from the
other [13, 14].
Factors that drive the selection of type 1 TAMs versus type
2 TAMs have not been thoroughly investigated. These might
include the genetic background of HIV-1 reverse transcriptase
(RT), immune selection pressure, and the particular type, se-
quence, and duration of TA use [13].
The prevalence of type 1 TAMs seems to be higher than
that of type 2 TAMs [9, 13, 14], the type 1 TAM profile is
associated with higher phenotypic resistance to NRTIs than
the type 2 TAM profile [15], and type 1 TAMs are associated
with impaired virological response to tenofovir-containing
therapy, whereas type 2 TAMs do not have such a detrimental
effect [16, 17]. However, mutations such as M41L, M184V,
L210W, and T215Y have been associated with a better, al-
though transient, virological outcome in patients treated with
efavirenz-based regimens [18].
F214L is a natural polymorphism detected in ∼18% of an-
tiretroviral therapy (ART)–naive and treated individuals [19].
Recently, a strong negative association between F214L and type
1 TAMs and, vice versa, a positive association between F214L
and type 2 TAMs have been observed [20]. Nevertheless, the
correlation between this polymorphism and virological re-
sponse to therapy in individuals starting combination ART
(cART) has not yet been investigated. The objectives of the
present analysis were as follows: first, to evaluate the prevalence
of F214L in the EuroSIDA cohort and its association with RT
resistance mutations and patterns of mutations; second, to as-
sess the virological response to a TA-based cART according to
the detection of F214L alone or concomitantly with specific
TAMs in both ART-naive and ART-experienced patients.
METHODS
Study population. Patients included were those starting zi-
dovudine or stavudine therapy for the first time while con-
comitantly receiving 2 other antiretrovirals (cART) and who
had been tested for genotypic resistance in the 6 months before
starting cART. Some patients were already TA experienced, but
only as mono- or dual-therapy before cART.
The majority of the genotypic tests ( ; 98.8%) usednp 583
in this analysis were performed retrospectively on stored plasma
in a central laboratory in Spain using standardized equip-
ment—the Trugene HIV-1 Genotyping Kit and the OpenGene
DNA Sequencing System (version 8.0)—in accordance with the
manufacturer’s recommendations. The remaining 1.2% of tests
had been performed at laboratories linked to the clinical sites
at which the patient was being followed up. All nucleotide
sequences have been deposited in GenBank; accession numbers
are EF563151–EF563824.
Phylogenetic analysis of the RT sequences was performed on
a subset of the included patients to determine HIV subtype.
We considered only RT mutations that have been associated
with zidovudine and/or stavudine resistance and listed by a
panel of European experts [21] plus mutations M184I/V, which
are known to confer hypersusceptibility to zidovudine and sta-
vudine [5, 22, 23]. Type 1 and type 2 TAM profiles were defined
similarly to other previous analyses [13, 14]. In particular, 2
definitions were used. One was a simple definition, with 1 or
more changes among M41L, L210W, and T215Y (with or with-
out D67N and no K70R or K219E/Q) being classified as a type
1 TAM profile. Similarly, the type 2 TAM profile was defined
as including 1 or more mutations among D67N, K70R, T215F,
and K219E/Q (and no M41L, L210W, or T215Y). Patients with
both type 1 and type 2 TAMs were classified in the mixed TAM
profile group and were typically patients with a large number
of TAMs. A second, stricter definition grouped patients ac-
cording to the detection of any combination of 2 mutations
among M41L, L210W, and T215Y (with or without D67N and
no type 2 TAMs) as a type 1 TAM profile; similarly, the type
2 TAM profile was classified by any combination of 2 mu-
tations among D67N, K70R, T215F, and K219E/Q (and no type
1 TAMs).
Statistical analysis. Associations between mutations were
tested using the x2 test and Fisher’s exact test, as appropriate.
No adjustment was used to control for multiple-hypothesis
testing; however, because, in addition to polymorphism 214L,
mutations at 17 other codons of the RT region were investi-
gated, associations were considered to be statistically significant
at (the conservative method of Bonferroni) [24].P ! .003
The virological response to therapy was evaluated using 2
separate approaches: analysis of the median reduction in the
week 24 viral load (VL) and time to virological failure. Week
24 VL reduction was calculated as the difference between the
VL measured at the time of starting the TA-containing cART
and the VL measured in a time window between 16 and 32
weeks. Because 26% of the patients had an undetectable VL at
this time point, the median VL reduction, both overall and in
subgroups, was calculated using the Kaplan-Meier approach to
account for the censored observations [25]. Accordingly, the
adjusted effect of specific mutations and of sets of mutations
on the week 24 VL reduction was evaluated using a linear
regression model that accounts for truncated values.
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Time to virological failure was defined as the time from
starting cART to the first of 2 consecutive VL measurements
1400 copies/mL after at least 6 months from the initiation of
the TA-containing cART. The follow-up of patients who did
not experience virological failure was censored at the time of
the last available VL. The analysis was conducted according to
an intention-to-continue-treatment principle by ignoring
changes in therapy. Kaplan-Meier estimates and proportional
hazards Cox regression models were used to test the prognostic
value of mutation F214L and other factors for predicting time
to virological failure. The Cox regression model was stratified
by clinical center. Survival analyses were repeated using an on-
treatment approach by censoring patients’ follow-up at the time
when the TA was interrupted (referred to as “on-treatment
analyses”). See the footnote of table 3 for a complete list of
potential confounders used in the multivariable analyses. In the
linear regression analysis, the exact number of weeks between
the date of starting cART and the week 24 VL measurement
was an additional covariate.
On the basis of previous findings [20, 26, 27], we tested in
ART-experienced patients the hypotheses that the virological
response associated with the detection of 214L (vs. 214F) could
be different according to the concomitant detection of different
mutations (specific TAMs or TAM profiles).
RESULTS
Characterization of the study population. The present anal-
ysis includes 590 patients from EuroSIDA, who started zido-
vudine or stavudine therapy for the first time as part of cART;
247 patients (42%) started zidovudine-containing regimens, the
remaining 343 (58%) started stavudine. The most frequently
used drugs besides the TAs were lamivudine ( [77%]),np 457
indinavir ( [28%]), ritonavir ( [27%]), didano-np 166 np 161
sine ( [15%]), and nevirapine ( [14%]). Overall,np 91 np 81
the types of TA-containing cART were 3 NRTIs ( [5%]),np 28
2 NRTIs plus a single protease inhibitor (PI) ( [49%]),np 291
2 NRTIs plus a nonnucleoside reverse transcriptase inhibitor
( [14%]), 2 NRTIs plus a ritonavir-boosted PI (np 84 np
[14%]), and other combinations containing 3 antiretrovirals82
( [7%]), 4 antiretrovirals ( [8%]), and 14 anti-np 40 np 46
retrovirals ( [3%]).np 19
The genotypic test was performed on average 1 month
(range, 0–6 months) before the initiation of the TA-containing
cART regimen (range, June 1995–June 2005).
Two hundred thirty-six patients (40%) were antiretroviral
naive when they were tested. For the remaining 354 patients,
the median number of antiretrovirals previously used was 3
(interquartile range [IQR], 2–4).
Prevalence of resistance mutations before the initiation of
TA-based cART. Using the simple definitions, we grouped
patients according to the observed pattern of TAMs as follows:
334 patients with no TAMs (57%), 137 (23%) with type 1
TAMs, 59 (10%) with type 2 TAMs, and 61 (10%) with a mixed
profile. Overall, polymorphism F214L was detected in 99 pa-
tients (17%). Table 1 shows the prevalence of F214L and RT
resistance mutations, both overall and according to patients’
treatment history. As expected, the prevalence of resistance mu-
tations was much higher in ART-experienced than ART-naive
patients.
There was evidence for a difference in the prevalence of
F214L in patients with no previous exposure to TA (5/22
[23%]) or previous exposure to zidovudine alone (41/284
[14%]) and with previous exposure to both zidovudine and
stavudine (14/48 [29%]) ( ). The prevalences of TAMsPp .03
in zidovudine-experienced patients were as follows: M41L
(47%), D67N (37%), K70R (33%), L210W (35%), T215F (7%),
T215Y (53%), K219E (6%), and K219Q (13%). In stavudine-
experienced patients, TAM prevalences were as follows: M41L
(39%), D67N (22%), K70R (20%), L210W (22%), T215F (7%),
T215Y (41%), K219E (2%), and K219Q (13%).
In ART-naive patients, the only significant association be-
tween the detection of F214L and all other RT mutations con-
sidered was for V118I (118I was present in 7 of 39 [18%] of
those with 214L vs. 2 of 197 [1%] of those with 214F; Pp
)..0003
In ART-experienced patients, several associations between
variant L/F at position 214 and TAMs were observed (figure
1). This analysis confirms previous observations that F214L is
less frequently detected in patients with type 1 TAMs or mixed
profiles than in those with type 2 TAMs or no TAMs.
HIV subtype data were available for 218 (92%) of the total
236 ART-naive patients, of whom 30 (14%) carried non-B sub-
types (4% A, 5% C, 0.5% D, 0.5% G, and 4% circulating
recombinant forms). No difference in the prevalence of 214L
in patients with subtype B versus patients with subtype non-B
was found.
Virological response to cART. In 236 patients who were
ART naive when they started the TA-containing cART, the over-
all average reduction in week 24 VLs after the initiation of
therapy was 2.77 (95% confidence interval [CI], 2.50–2.95) log10
copies/mL. This reduction was 0.48 (95% CI, 0.16 to 1.12;
) log10 copies/mL greater in patients with 214L than inPp .14
those with 214F, after controlling for confounders in a linear
regression model. By 48 months after starting the TA-based
cART, the proportion of patients who experienced virological
failure was 16% (95% CI, 4%–28%) in patients with the 214L
variant and 36% (95% CI, 28%–44%) in those with the 214F
variant ( ) (figure 2). The median number of VL mea-Pp .03
surements during follow-up was similar in the 2 groups: 3.4
(IQR, 2.5–4.1) per year in patients with 214F and 3.2 (IQR,
2.3–4.1) per year in those with 214L.
In the Cox regression model, the relative hazard (RH) of
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Table 1. Prevalence of polymorphism F214L and a no. of drug-resistance
mutations in the reverse transcriptase (RT) region, according to patients’ treat-
ment history.
Mutation
ART status
Total PExperienced Naive
RT mutation
41L 158 (44.6) 7 (3.0) 165 (28.0) .0001
44A/D 50 (14.1) 2 (0.9) 52 (8.8) .0001
62V 11 (3.1) 2 (0.9) 13 (2.2) .09
65R 4 (1.1) 0 (0.0) 4 (0.7) .15
67G/N 127 (35.9) 6 (2.5) 133 (22.5) .0001
70R 110 (31.1) 2 (0.9) 112 (18.9) .0001
74I/V 14 (4.0) 1 (0.4) 15 (2.5) .008
75A/I/M/S/T 2 (0.6) 0 (0.0) 2 (0.3) .52
77L 3 (0.9) 0 (0.0) 3 (0.5) .28
116Y 1 (0.3) 0 (0.0) 1 (0.2) 1.00
118I 51 (14.4) 9 (3.8) 60 (10.2) .0001
151M 1 (0.3) 0 (0.0) 1 (0.2) 1.00
184I/V 198 (55.9) 5 (2.1) 203 (34.4) .0001
210W 119 (33.6) 4 (1.7) 123 (20.9) .0001
214L 60 (17.0) 39 (16.5) 99 (16.8) .89
215F 23 (6.5) 1 (0.4) 24 (4.1) .0003
215Y 177 (50.0) 3 (1.3) 180 (30.5) .0001
219E/H/N/Q/R 73 (20.6) 6 (2.5) 79 (13.4) .0001
TAM profile
No TAMs 109 (30.8) 225 (95.3) 334 (56.6) .0001
Simple definition
Type 1 TAM 130 (36.7) 7 (3.0) 137 (23.2) .0001
Type 2 TAM 54 (15.3) 4 (1.7) 58 (9.8) .0001
Mixed TAM 61 (17.2) 0 (0.0) 61 (10.3) .0001
Strict definition
Type 1 TAM 117/275 (43.0) 7/236 (3.0) 124/511 (24.3) .0001
Type 2 TAM 49/275 (17.8) 4/236 (1.7) 53/511 (10.4) .0001
Total 354 236 590
NOTE. Data are no. (%) of patients, unless otherwise indicated. P values are from a x2
test (or Fisher’s exact test, when appropriate) to test the hypothesis that the prevalence of
specific mutations or profiles is different between antiretroviral therapy (ART)–naive and ART-
experienced patients. TAM, thymidine analogue mutation.
virological failure for patients with 214L compared with those
with 214F was 0.22 (95% CI, 0.07–0.72; ) (table 2).Pp .01
Also, older patients tended to be less likely to experience vi-
rological failure (RH per 10 years older age, 0.77 [95% CI,
0.58–1.01]; ). No significant difference in virologicalPp .06
response was found between patients starting a zidovudine-
containing cART and those starting a stavudine-containing
cART ( ). Also, there was no evidence that the differencePp .90
in virological response associated with the detection of 214L
versus 214F was different according to which TA was started
(RH for 214L vs. 214F, 0.10 in those starting zidovudine ther-
apy vs. 0.18 in those starting stavudine therapy; P for
). Results were similar when we repeated theinteractionp .44
analysis using the on-treatment approach (data not shown).
In ART-experienced patients, the virological response was
also better in patients with variant 214L than in those with
214F. The week 24 VL reduction was 1.75 log10 (95% CI, 0.98–
3.00) copies/mL in patients with 214L and was 1.35 (95% CI,
1.08–1.64) log10 copies/mL in those with 214F ( , log-Pp .02
rank test). In the multivariable analysis, patients with 214L had
a greater VL reduction from baseline than those with 214F,
although it was not statistically significant (adjusted mean dif-
ferences of 214L vs. 214F, 0.19 [95% CI, 0.28 to +0.65];
).Pp .44
By 48 months after starting the TA-based cART, the pro-
portion of patients who experienced virological failure was 47%
(95% CI, 33%–61%) in patients with 214L and was 72% (95%
CI, 66%–78%) in those with 214F ( ). The medianPp .007
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Figure 1. Proportion of patients with reverse transcriptase mutations and mutational profiles, according to concomitant detection of 214F or 214L
polymorphism. P values shown above the bars are from x2 tests; associations are considered to be statistically significant if . TAM, thymidineP ! .003
analogue mutation.
number of VL measurements during follow-up was 4.0 (IQR,
3.4–5.1) in patients with 214F and was 4.0 (IQR, 3.0–4.7) in
those with 214L. In the multivariable survival analysis, the de-
tection of polymorphism 214L versus 214F before initiation of
the TA-containing cART regimen was significantly associated
with a lower risk of virological failure (adjusted RH, 0.63 [95%
CI, 0.42–0.96]; ). Interestingly, in this survival analysisPp .03
we found no evidence for a difference in risk of virological
failure associated with the detection of polymorphism 214L
according to concomitant detection of TAMs and TAM profiles
(P values for the test of interactions were as follows: for 41L,
; for 215Y, , and for mixed profiles, ).Pp .07 Pp .33 Pp .22
In contrast, in the linear regression analysis, a larger difference
in week 24 VL reductions between patients with 214L and those
with 214F appeared to be in patients who concomitantly har-
bored 41L, 215Y, or mixed profiles before the initiation of the
TA-containing cART (table 3). The P values for the test of
interactions were as follows: for M41L, ; for E44A/D,Pp .03
; for D67N, ; for K70R, ; for V118I,Pp .25 Pp .51 Pp .59
; for L210W, ; for T215Y, ; for K219E/Pp .90 Pp .19 Pp .001
Q, ; for type 1 TAMs, ; for type 2 TAMs,Pp .97 Pp .56
; and for mixed profiles, .Pp .91 Pp .02
When the overall effect of TAMs on virological response was
analyzed, compared with that in patients in whom no TAMs
were detected, the mean reductions in VL were +0.65 (95%
CI, +0.22 to +1.07) log10 copies/mL for those with type 1 TAMs
( ), +0.54 (95% CI, +0.02 to +1.05) log10 copies/mLPp .003
for those with type 2 TAMs ( ), and +0.71 (95% CI,Pp .04
+0.22 to +1.20) log10 copies/mL for those with mixed profiles
( ).Pp .005
Again, the on-treatment analysis provided similar results
(data not shown). Similar results both in ART-naive and ART-
experienced patients were found when the analysis was re-
stricted to those who initiated a PI-based cART regimen (RH,
0.36 [95% CI, 0.19–0.68]; ).Pp .002
HIV evolution according to the detection of F214L
polymorphism. Finally, to test whether the detection of F214L
before therapy was associated with the subsequent observation
of a specific TAM pathway, we performed an analysis in the
subsets of patients who had an additional genotype available
after starting therapy and in whom specific TAMs could not
be detected by genotypic testing before starting the TA-con-
taining cART. Overall, the median time from the date of starting
therapy to this second test was 18 (range, 2–88) months. In
these subsets (for which the sample size ranged from np
in the 215Y development analysis to in the 219E/135 np 221
Q development analysis), the proportion of patients who har-
bored the 214L variant was 17%. The proportions of people
with 214L vs. those with 214F who appeared to have accu-
mulated specific TAMs were as follows: for 41L, 4% versus 12%
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Figure 2. Kaplan-Meier curves for probability of virological failure (2 consecutive viral load measurements 1400 copies/mL after at least 6 months of
thymidine analogue [TA]–containing combination antiretroviral therapy [cART]), according to the detection of variant L or F at position 214 of the reverse
transcriptase region in ART-naive patients starting TA-containing cART.
( ); for 210W, 0% versus 7% ( ); for 215Y, 4%Pp .47 Pp .36
versus 7% ( ); for 67N, 13% versus 10% ( ); forPp 1.00 Pp .71
70R, 14% versus 5% ( ), and for 219E/Q, 9% versus 8%Pp .13
( ). These findings are consistent with a pathway ag-Pp 1.00
onistic to type 2 TAM profiles and antagonistic to type 1 TAM
profiles in people harboring 214L at the pretherapy test. Finally,
of 15 patients with no TAMs and 214L at the pretherapy test,
12 (80%) developed 1 TAM after treatment initiation; of 84
patients with no TAMs and 214F, 72 (86%) developed1 TAM
( ).Pp .57
DISCUSSION
This is, to our knowledge, the first large study providing ev-
idence that the detection of polymorphism F214L may con-
fer virological benefit to patients starting a zidovudine- or stav-
udine-containing cART. Larger week 24 VL reductions were
observed in both ART-naive and ART-experienced patients
carrying F214L, and this persisted during more extended
follow-up, as evidenced by a lower hazard of virological failure.
These analyses were conducted according to an intention-to-
treatment principle by ignoring changes in therapy; therefore,
results may not be due to continued exposure to the TAs.
However, results were similar when analyses were repeated us-
ing an on-treatment approach that censored events at the date
of interruption of TAs.
Interestingly, the relevance of F214L for virological response
to combination therapy has already been suggested in 2 pre-
vious studies. In 55 patients enrolled in the ACTG241 trial,
mutations in baseline sequences at positions 214, 196, and 200
were associated with a stronger response to didanosine-zido-
vudine–containing therapy at week 48 [28]. Similarly, in 111
patients enrolled in the Jaguar trial, F214L was associated with
a better virological response to didanosine at week 4 [26]. How-
ever, in our analysis, we did not find evidence of a different
association between 214L/F and virological outcome according
to whether didanosine was or was not used in the regimen
(data not shown), suggesting that a favorable response to TA-
containing regimens may be expected irrespective of which
other NRTI is used.
The benefit of virological response associated with the de-
tection of F214L versus 214F in the HIV-1 RT may be partially
due to the strong negative association between F214L and type
1 TAMs [20, 26, 27]. Although the association between 214L
and virological response to TA-containing cART was indepen-
dent of predicted TA activity at baseline, it is conceivable that
the particular dominant variant at position 214 before the ini-
tiation of therapy may represent one of the determinants for
TAM pathway choice; thus, 214L, by inhibiting the develop-
ment of type 1 TAMs or a large number of TAMs (as in mixed
profiles), may provide a favorable effect on virological response.
Generally, the prevalence of type 1 TAMs is higher than that
of type 2 TAMs in NRTI-treated patients [9, 12–14, 29]. In
agreement with these data, in our cohort of ART-experienced
patients, the prevalence of type 1 TAM profiles was much higher
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Table 2. Adjusted relative hazards (RHs) of virological failure from fitting a proportional hazards Cox
regression model for antiretroviral therapy (ART)–naive and ART-experienced patients.
Factor
ART naive ART experienced
RH (95% CI) P RH (95% CI) P
Age, per 10 years older 0.77 (0.58–1.01) .06 0.91 (0.78–1.08) .28
RT214
F 1.00 1.00
L 0.22 (0.07–0.72) .01 0.63 (0.42–0.96) .03
Viral load, per log10 copies/mL 1.13 (0.77–1.66) .52 1.26 (1.06–1.50) .008
Susceptibility to thymdine analoguea
Susceptible 1.00 1.00
Intermediate 3.45 (0.32–37.6) .31 1.08 (0.72–1.64) .70
Resistance 2.43 (0.31–19.3) .40 1.08 (0.78–1.50) .64
No. of active drugsa in regimen besides
zidovudine/stavudine, per additional drug 0.57 (0.28–1.19) .04 0.72 (0.58–0.91) .005
Time from test to cART initiation, per month longer 1.14 (1.00–1.31) .05 1.05 (0.97–1.13) .25
NOTE. RHs are adjusted for sex, mode of HIV transmission, exact no. of weeks between the date of genotypic test
and the date of starting combination ART (cART), whether a patient started zidovudine- or stavudine-containing cART,
previous use of thymidine analogues as suboptimal therapy, use of dideoxyinosine, and third drug used (with efavirenz as
the comparator) at the time of starting zidovudine or stavudine therapy. CI, confidence interval; RT, reverse transcriptase.
a Per the Rega Institute interpretation system (version 6.4.1).
than that of type 2 TAM profiles irrespective of the concom-
itant detection of F214L (37% vs. 15% with the simple def-
inition; 43% vs. 18% with the strict definition; ).P ! .0001
Our analysis also confirms, as previously observed in other
studies [20, 26], that F214L in ART-experienced patients is
strongly negatively associated with M41L, L210W, T215Y, type
1 TAM profiles, and mixed TAM profiles and is positively
associated with type 2 TAM profiles. A stabilizing mechanism
explained by the structural vicinity of positions 214 and type
1 TAMs 215 and 210 may drive this clustering phenomenon
[20] (F.C.-S., A. Artese [University of Catanzaro Magna Gras-
cia, Roccelletta di Borgia, Italy], S. Alcaro [University of Ca-
tanzaro Magna Grascia, Roccelletta di Borgia, Italy], and
C.F.P., unpublished data). Indeed, a background of 214F (in-
stead of 214L), because of the interaction of the aromatic side
chains, may favor and stabilize the enzyme of virus popula-
tions carrying mutation T215Y, which is normally the first
occurring type 1 TAM [30], and the following L210W (F, W,
and Y contain aromatic side chains); in contrast, polymor-
phism 214L does not have aromatic side chains and, therefore,
may not increase the stability of the 3-dimensional structure
of the enzyme in the presence of type 1 TAMs.
A low stability of RT enzymes harboring 214L and type 1
TAMs and mixed TAM profiles may induce a low level of viral
replication and also explain the markedly better virological re-
sponse to TA-containing cART observed in patients with 214L
than in those with 214F when M41L, T215Y, or, in general, a
type 1 TAM or mixed TAM profile was concomitantly detected.
Consistent with this hypothesis, it has been proposed that virus
populations carrying a type 1 TAM profile are less susceptible
to zidovudine and stavudine in the presence of 214F instead
of 214L [27] and that 214F may improve the efficacy of the
ATP-mediated removal of the zidovudine and stavudine mon-
ophosphate from the terminated cDNA chain [31]. Finally, in
2 separate analyses of genotypic-phenotypic correlations, F214L
was associated with an increased susceptibility to didanosine
[32] and tenofovir [33].
Therefore, all of these data suggest that F214L, either alone
or in combination with specific mutations, may alter the RT
structure, impacting viral fitness and/or drug susceptibility and
thus affecting the response to TAs as well as to other antiret-
rovirals. More phenotypic and clinical data are necessary to
confirm these observations, and the exact molecular mecha-
nism responsible for the action of polymorphism F214L needs
to be further investigated. For example, it is still unclear
whether the course of HIV-1 evolution (from wild type to type
1 TAMs and type 2 TAMs) under pressure of a TA can be
influenced by the presence of such a polymorphism, either
alone or with other mutations and/or factors. In our analysis,
even if the results were not statistically significant (possibly due
to the lack of power; the maximum sample size was 221), a
trend toward a greater accumulation of type 2 TAMs was ob-
served in patients in whom the 214L variant instead of the 214F
variant was detected at baseline. These data are in agreement
with those of another recent study [34].
Overall, even if this is a large study focusing on F214L and
virological response, a limitation is the fact that a longitudinal
analysis using 11 genotype per patient could be performed only
in a small subset of patients, not all of whom were drug naive.
We cannot exclude the possibility that past suboptimal mono-
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Table 3. Average difference in week 24 viral load reduction between patients with
variant 214L or 214F, according to specific mutations and to mutation profiles con-
comitantly detected.
Mutation
214L vs. 214F
Crude difference,
mean (95% CI)
Adjusted differencea
Mean (95% CI) P for interaction
RT mutation
41
M 0.20 (0.42 to 0.81) 0.16 (0.77 to 0.46)
L 0.94 (0.06 to 1.82) 0.83 (0.09 to 1.57) .03
215
T 0.05 (0.54 to 0.64) 0.08 (0.66 to 0.49)
Y 1.13 (0.16 to 2.09) 1.02 (0.20 to 1.85) .001
TAM profile
No TAMs 0.25 (0.56 to 1.06) 0.04 (0.78 to 0.87)
Type 1 TAMb 0.26 (0.92 to 1.44) 0.52 (0.43 to 1.46) .56
Type 2 TAMb 0.35 (1.25 to 0.56) 1.38 (2.22 to 0.52) .91
Mixed TAM 1.51 (0.40 to 2.62) 1.35 (0.45 to 2.26) .02
NOTE. Data are no. (%) of patients, unless otherwise indicated. CI, confidence interval; RT, reverse
transcriptase; TAM, thymidine analogue mutation.
a Adjusted for sex, age, mode of HIV transmission, pre–combination antiretroviral therapy (cART)
viral load, exact no. of weeks between the date of genotypic test and the date of starting cART, whether
a patient started a zidovudine- or stavudine-containing cART, whether zidovudine or stavudine were
active (according to the Rega Institute interpretation system [version 6.4.1]), the no. of drugs besides
zidovudine and stavudine to which virus was susceptible (according to Rega), previous use of thymidine
analogues as suboptimal therapy, use of dideoxyinosine, the third drug used (with efavirenz as the
comparator) at the time of starting zidovudine or stavudine therapy, and the exact no. of weeks between
the date of starting cART and the week 24 viral load measurement.
b Simple definition.
therapy or dual therapy with TAs may have already influenced
the evolution of minor variants without apparently selecting
TAMs before the initiation of cART. Therefore, further inves-
tigations using larger databases are warranted to confirm
whether the detection of F214L in drug-naı¨ve patients favors
the selection of type 2 TAMs versus type 1 TAMs. Indeed, this
issue is of high relevance for researchers and clinicians, because
these 2 distinct TAM clusters have diverse clinical significance:
type 1 TAMs are associated with higher phenotypic resistance
to zidovudine and higher cross-resistance to other NRTIs (such
as didanosine and tenofovir) than type 2 TAMs [15, 16, 29,
35–37]. A type 1 TAM profile is associated with an impaired
virological response to tenofovir-containing therapy and with
a 1.8-fold increase in the risk of disease progression and/or
death, whereas a type 2 TAM profile does not have a detrimental
effect [16, 17, 38, 39].
The prevalence of 214F/L was not different according to HIV
subtype in our study. This is inconsistent with what has been
found in other study populations. For instance, the preva-
lence of 214L in drug-naive patients varies from 2.5% (subtype
AE) to 17.8% (subtype D) [5]. Therefore, further investiga-
tion of the virological response to TA-based cART according
to the detection of 214L in patients carrying non-B subtypes
is warranted.
In conclusion, the present study provides evidence that pa-
tients with the natural polymorphism F214L have a better vi-
rological response to TA-containing cART than those with 214F.
Sequencing the RT region is currently recommended in treat-
ment-naive patients about to start therapy if the suspicion of
transmitted resistance is high or if its prevalence in the pop-
ulation exceeds 10% [40]. Therapy choice might benefit from
taking polymorphisms at codon 214 into account as potential
contributors to the future course of resistance evolution and
response to first-line treatment with zidovudine. The consid-
erable prevalence of this polymorphism (16%–18%) and its
relevance at the time of treatment selection strongly argue in
favor of extended the genotyping of all patients starting ART.
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